About 200 reports

  • A) Global immunology market size
  • IMMUNOLOGY SPECIALIZATION, 2017
  • Immunology
  • World
  • AbbVie Inc.
  • Janssen Biotech, Inc.
  • Johnson & Johnson
  • IMMUNOLOGY MARKET IN APAC
  • Market size: Global immunology market
  • Immunology
  • World
  • AbbVie Inc.
  • Amgen Inc.
  • F. Hoffmann-La Roche Ltd.

Immunology royalty rates Chapter ## – Leading Immunology deals and dealmakers ##. ##.

  • Health Services
  • Immunology
  • World
  • IMMUNOLOGY THERAPEUTICS MARKET, GLOBAL, PIPELINE FOR IMMUNOLOGY BY STAGE OF
  • IMMUNOLOGY THERAPEUTICS MARKET, GLOBAL, PIPELINE FOR KEY IMMUNOLOGY
  • Immunology
  • World
  • Market Size
  • Johnson & Johnson
  • Novartis AG
  • 3.4.4 Immunology
  • 4.2.4 Immunology
  • Immunology
  • Pharmaceutical
  • Therapy
  • Europe
  • Market Size
  • Immunology Market
  • Versatile Innovation in Immunology, Global,
  • Health Services
  • Healthcare
  • Immunology
  • World
  • GlaxoSmithKline plc
  • La Jolla Institute for Allergy & Immunology - Locations And Subsidiaries
  • La Jolla Institute for Allergy & Immunology, Key Competitors
  • Immunology
  • Pharmaceutical
  • United States
  • Deals & Alliance
  • GlobalData's company
  • Institute for Research in Immunology and Cancer, Key Competitors
  • Institute for Research in Immunology and Cancer - Locations And Subsidiaries
  • Health Services
  • Immunology
  • Pharmaceutical
  • Canada
  • GlobalData's company
  • PROPORTION OF CORNEAL GRAFT REJECTION TO IMMUNOLOGY CLINICAL TRIALS, G7 COUNTRIES (%), 2017*
  • PROPORTION OF CORNEAL GRAFT REJECTION TO IMMUNOLOGY CLINICAL TRIALS, G7 COUNTRIES (%), 2017*
  • Clinical Trial
  • Immunology
  • World
  • Product Initiative
  • Oxford BioMedica plc
  • SYNTHETIC PEPTIDES TO AGONIZE FPR1/2 FOR IMMUNOLOGY AND INFECTIOUS DISEASE - DRUG PROFILE
  • SYNTHETIC PEPTIDES TO ANTAGONIZE FPR1/2 FOR IMMUNOLOGY AND INFECTIOUS DISEASE - DRUG PROFILE
  • Immunology
  • Pathology
  • Therapy
  • World
  • Product Initiative
  • 7.4 PHARMACEUTICALS & HEALTHCARE, GLOBAL, IMMUNOLOGY DEALS, Q4 2016
  • Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal
  • Endocrine Disease
  • Immunology
  • World
  • Deals & Alliance
  • AstraZeneca PLC
  • 5.5 PHARMACEUTICALS & HEALTHCARE, GLOBAL, IMMUNOLOGY DEALS, OCTOBER 2017
  • 5.5 PHARMACEUTICALS & HEALTHCARE, GLOBAL, IMMUNOLOGY DEALS, AUGUST 2017
  • Immunology
  • Pharmaceutical
  • World
  • Company
  • Deals & Alliance
  • PROPORTION OF HEREDITARY ANGIOEDEMA (HAE) (C1 ESTERASE INHIBITOR [C1-INH] DEFICIENCY) TO IMMUNOLOGY CLINICAL TRIALS, E7
  • PROPORTION OF HEREDITARY ANGIOEDEMA (HAE) (C1 ESTERASE INHIBITOR [C1-INH] DEFICIENCY) TO IMMUNOLOGY CLINICAL TRIALS, E7
  • Clinical Trial
  • Immunology
  • World
  • Product Initiative
  • Shire plc
  • PROPORTION OF DRUG HYPERSENSITIVITY REACTIONS TO IMMUNOLOGY CLINICAL TRIALS, G7 COUNTRIES (%), 2017*
  • PROPORTION OF DRUG HYPERSENSITIVITY REACTIONS TO IMMUNOLOGY CLINICAL TRIALS, G7 COUNTRIES (%), 2017*
  • Immunology
  • Pharmaceutical
  • Therapy
  • World
  • Product Initiative
  • PROPORTION OF CUTANEOUS LUPUS ERYTHEMATOSUS TO IMMUNOLOGY CLINICAL TRIALS, G7 COUNTRIES (%), 2017*
  • PROPORTION OF CUTANEOUS LUPUS ERYTHEMATOSUS TO IMMUNOLOGY CLINICAL TRIALS, E7 COUNTRIES (%), 2017*
  • Clinical Trial
  • Immunology
  • Musculoskeletal Disorder
  • World
  • Product Initiative
  • CLINICAL TRIALS BY E7 COUNTRIES: PROPORTION OF CHRONIC INFLAMMATION TO IMMUNOLOGY CLINICAL TRIALS
  • PROPORTION OF CHRONIC INFLAMMATION TO IMMUNOLOGY CLINICAL TRIALS, E7 COUNTRIES (%), 2017*
  • Clinical Trial
  • Immunology
  • World
  • Product Initiative
  • Merck & Co., Inc.
  • PROPORTION OF CHRONIC CUTANEOUS LUPUS ERYTHEMATOSUS (CCLE) / DISCOID LUPUS ERYTHEMATOSUS (DLE) TO IMMUNOLOGY CLINICAL
  • PROPORTION OF CHRONIC CUTANEOUS LUPUS ERYTHEMATOSUS (CCLE) / DISCOID LUPUS ERYTHEMATOSUS (DLE) TO IMMUNOLOGY CLINICAL
  • Dermatological Condition
  • Immunology
  • World
  • Product Initiative
  • Celgene Corporation
  • PROPORTION OF CHURG-STRAUSS SYNDROME TO IMMUNOLOGY CLINICAL TRIALS, E7 COUNTRIES (%), 2017*
  • PROPORTION OF CHURG-STRAUSS SYNDROME TO IMMUNOLOGY CLINICAL TRIALS, E7 COUNTRIES (%), 2017*
  • Hospital
  • Immunology
  • Monoclonal Antibody
  • World
  • Product Initiative
  • PROPORTION OF BIRCH POLLEN ALLERGY TO IMMUNOLOGY CLINICAL TRIALS, G7 COUNTRIES (%), 2017*
  • PROPORTION OF BIRCH POLLEN ALLERGY TO IMMUNOLOGY CLINICAL TRIALS, G7 COUNTRIES (%), 2017*
  • Allergy Drug
  • Immunology
  • World
  • Product Initiative
  • Anergis SA
  • PROPORTION OF JUVENILE RHEUMATOID ARTHRITIS TO IMMUNOLOGY CLINICAL TRIALS, G7 COUNTRIES (%), 2017*
  • PROPORTION OF JUVENILE RHEUMATOID ARTHRITIS TO IMMUNOLOGY CLINICAL TRIALS, E7 COUNTRIES (%), 2017*
  • Immunology
  • Monoclonal Antibody
  • World
  • Product Initiative
  • Pfizer Inc.
  • PROPORTION OF MUCOCUTANEOUS LYMPH NODE SYNDROME (KAWASAKI DISEASE) TO IMMUNOLOGY CLINICAL TRIALS, G7 COUNTRIES (%),
  • CLINICAL TRIALS BY G7 COUNTRIES: PROPORTION OF MUCOCUTANEOUS LYMPH NODE SYNDROME (KAWASAKI DISEASE) TO IMMUNOLOGY CLINICAL TRIALS
  • Immunology
  • Monoclonal Antibody
  • World
  • Product Initiative
  • Mitsubishi Corporation
  • PROPORTION OF ANGIOEDEMA TO IMMUNOLOGY CLINICAL TRIALS, G7 COUNTRIES (%), 2017*
  • Clinical Trials by E7 Countries: Proportion of Angioedema to Immunology Clinical Trials
  • Allergy Drug
  • Immunology
  • World
  • Product Initiative
  • Shire plc
  • Clinical Trials by E7 Countries: Proportion of Kidney Transplant Rejection to Immunology Clinical Trials
  • PROPORTION OF KIDNEY TRANSPLANT REJECTION TO IMMUNOLOGY CLINICAL TRIALS, G7 COUNTRIES (%), 2017*
  • Clinical Trial
  • Immunology
  • Prosthesis
  • Transplantation
  • Novartis AG
  • PROPORTION OF CEDAR POLLEN ALLERGY TO IMMUNOLOGY CLINICAL TRIALS, G7 COUNTRIES (%), 2017*
  • CLINICAL TRIALS BY G7 COUNTRIES: PROPORTION OF CEDAR POLLEN ALLERGY TO IMMUNOLOGY CLINICAL TRIALS
  • Allergy Drug
  • Immunology
  • Japan
  • World
  • Product Initiative
  • PROPORTION OF MILK ALLERGY TO IMMUNOLOGY CLINICAL TRIALS, G7 COUNTRIES (%), 2017*
  • CLINICAL TRIALS BY G7 COUNTRIES: PROPORTION OF MILK ALLERGY TO IMMUNOLOGY CLINICAL TRIALS
  • Biological Therapy
  • Immunology
  • Milk
  • World
  • Product Initiative
  • CLINICAL TRIALS BY E7 COUNTRIES: PROPORTION OF HEMATOPOIETIC STEM CELL TRANSPLANTATION TO IMMUNOLOGY CLINICAL TRIALS
  • PROPORTION OF HEMATOPOIETIC STEM CELL TRANSPLANTATION TO IMMUNOLOGY CLINICAL TRIALS, G7 COUNTRIES (%), 2017*
  • Biological Therapy
  • Blood Disease
  • Immunology
  • World
  • Product Initiative
  • PROPORTION OF ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS (ANCA VASCULITIS) TO IMMUNOLOGY CLINICAL TRIALS, E7
  • Clinical Trials by E7 Countries: Proportion of Anti-Neutrophil Cytoplasmic Antibody- Associated Vasculitis (ANCA Vasculitis) to Immunology Clinical Trials
  • Autoimmune Disease
  • Immunology
  • Monoclonal Antibody
  • World
  • Product Initiative
  • Proportion of Lambert-Eaton Myasthenic Syndrome (LEMS) to Immunology Clinical Trials, G7 Countries (%), 2016*
  • PROPORTION OF LAMBERT-EATON MYASTHENIC SYNDROME (LEMS) TO IMMUNOLOGY CLINICAL TRIALS, E7 COUNTRIES (%), 2017*
  • Immunology
  • Neurological Disorder
  • World
  • Product Initiative
  • Catalyst Pharmaceuticals, Inc.
  • PROPORTION OF CAT ALLERGY TO IMMUNOLOGY CLINICAL TRIALS, E7 COUNTRIES (%), 2017*
  • CLINICAL TRIALS BY E7 COUNTRIES: PROPORTION OF CAT ALLERGY TO IMMUNOLOGY CLINICAL TRIALS
  • Clinical Trial
  • Immunology
  • World
  • Product Initiative
  • Circassia Pharmaceuticals plc
  • PROPORTION OF HEART TRANSPLANT REJECTION TO IMMUNOLOGY CLINICAL TRIALS, G7 COUNTRIES (%), 2017*
  • PROPORTION OF HEART TRANSPLANT REJECTION TO IMMUNOLOGY CLINICAL TRIALS, E7 COUNTRIES (%), 2017*
  • Heart Transplant
  • Immunology
  • World
  • Product Initiative
  • Novartis AG